Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193056 | 1.00 | GGT1 (0.39) | GGT1ARG1ARG2ACLY | |
| SCHEMBL6059925 | 1.00 | GGT1 (0.39) | GGT1ARG1ARG2ACLY | |
| SCHEMBL6059928 | 1.00 | GGT1 (0.39) | GGT1ARG1ARG2ACLY | |
| SCHEMBL5830041 | 1.00 | GGT1 (0.39) | GGT1ARG1ARG2ACLY | |
| SCHEMBL6192147 | 1.00 | GGT1 (0.39) | GGT1ARG1ARG2ACLY | |
| SCHEMBL6192143 | 1.00 | GGT1 (0.39) | GGT1ARG1ARG2ACLY | |
| Hydrochloric Acid SCHEMBL6191468 | 0.99 | GGT1 (0.38) | GGT1ARG1ARG2ACLY | |
| Hydrochloric Acid SCHEMBL6194565 | 0.99 | GGT1 (0.38) | GGT1ARG1ARG2ACLY | |
| SCHEMBL6191048 | 0.86 | — | — | |
| SCHEMBL27557670 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951889-B2 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | claimed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | claimed |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-05-26 | — | — | US | claimed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | claimed |
| EP-1317421-B1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORP (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040225150-A1 | Methods for selectively removing counterions from compounds and compounds derived from such methods | PHARMACIA & UPJOHN COMPANY | 2004-11-11 | — | — | US | claimed |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | MANNING PAMELA T (US) | 2004-04-22 | — | — | US | claimed |
| EP-1317421-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-09-19 | — | — | US | claimed |
| WO-2002022562-A1 | 2-AMINO-2-ALKYL-5 HEPTENOIC AND HEPTYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | claimed |
| US-7012098-B2 | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers | PHARMACIA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| US-6995281-B2 | Methods for selectively removing counterions from compounds and compounds derived from such methods | PFIZER, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1463495-A4 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORP (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6951889-B2 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | PHARMACIA CORPORATION | 2005-09-15 | — | — | US | disclosed |
| WO-2003026638-A1 | NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026668-A1 | OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | GGT1 141/4885ARG1 482/4885ARG2 315/4885 |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | NOS2, NOS1, NOS3 | GGT1 205/4885ARG1 9/4885ARG2 4/4885 |
| US-20050203082-A1 | Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents | NOS2, NOS1, NOS3 | GGT1 276/4885ARG1 5/4885ARG2 9/4885 |
| US-20040225150-A1 | Methods for selectively removing counterions from compounds and compounds derived from such methods | BHMT2, MGMT, BHMT | GGT1 355/4885ARG1 1652/4885ARG2 363/4885 |
| US-20020132849-A1 | 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | GGT1 803/4885ARG1 583/4885ARG2 275/4885 |
| US-20050113451-A1 | 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | PTGIS, ALOX5, ALOX15 | GGT1 803/4885ARG1 583/4885ARG2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.